Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq

• Manhattan Study: Observational, Ambispective Study to Describe Persistence and …
• https://x.com/RichardPAConway/status/1858194388360282291/photo/1

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/IOzckJIfYf https://t.co/8S6FnffVLG

Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3

• Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients w…
• https://x.com/RichardPAConway/status/1858187341455573295/photo/1

Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF

• https://x.com/EBRheum/status/1858188599910703531/photo/1

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

Are biosimilar multi-switches an issue? real world data: DANBIO 🇩🇰 biosimilar to biosimilar switch having already had a switch prior ('previous ADAo') did not increase cessation The risk of biosimilar switching on immunogenicity is greatly overstated #ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0

• https://x.com/drdavidliew/status/1858180360288526800/photo/1

Single centre experience of belimumab at @GSTTnhs @RheumNow #ACR24 https://t.co/c4jlEPRwen

• https://twitter.com/sahilja09303150/status/1858168844587598111

#2282 🔬 Personalised Approach to TNFi in RA 📊 N=50👇; 43 responders 🔑 Findings 💥TNFR2 rs1061622 polymorphism linked to TNFi response 💥 MR/RR alleles ⬆️ 10X odds non-response v. MM allele (OR = 10.1,p=0.04) 🎯Genotyping may guide personalized RA therapy. #ACR24 @RheumNow https://t.co/MQKZUCEPxj

• https://x.com/CaoilfhionnMD/status/1858168467213475893/photo/1

#1474 🔬Severe PsA? Guselkumab (GUS) has promise! ➡️In bionaive pts with severe disease activity, GUS v. PBO resulted in: 🔴73% improvement in joints 🔴53% lower disease activity 🔴63% better PtGA by 2 years ➡️Rapid results by W2, sustained through W100. #ACR @RheumNow

Improved fertility in women with RA when treated with a Treat-to-Target (T2T) approach aimed at remission. Key findings: - Shorter time to pregnancy (TTP) in PreCARA cohort (84 days) vs. PARA cohort (196 days). - Increased TNF-inhibitor use and lower NSAID/prednisone use in the… https://t.co/YyD2lpXVRC https://t.co/LH5LMOH8al

• https://x.com/i/web/status/1858149341715698133
• https://x.com/synovialjoints/status/1858149341715698133/photo/1

The post hoc analysis of the SURPASS study evaluated predictors of radiographic spinal progression in axial spondyloarthritis patients treated with IL-17A (secukinumab) or TNF inhibitors over 2 years. Key findings: - New syndesmophytes: 18.2% (SEC 150 mg), 15.8% (SEC 300 mg),… https://t.co/jke6OHdPjZ

• https://x.com/i/web/status/1858151857870315827